Skip to main content
Clinical Trials/CTRI/2021/07/034813
CTRI/2021/07/034813
Completed
Phase 2

A pilot study to evaluate the feasibility and efficacy of dexamethasone free anti emetic regimen in patients receiving highly emetogenic chemotherapy

CI AIIMS0 sites101 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
CI AIIMS
Enrollment
101
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
October 28, 2021
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
CI AIIMS

Eligibility Criteria

Inclusion Criteria

  • a. Diagnosis of malignancy
  • b. No prior chemotherapy and radiation therapy (RT)
  • c. Age of ââ?°Â¥ 18 ââ?¬â?? up to 70 years
  • d. ECOG Performance status (0\-2\)
  • e. Complete hemogram (ANC ââ?°Â¥1000/m3, TLC ââ?°Â¥3000/m3, Platelets ââ?°Â¥ 1,00,000/m3\), Creatinine (ââ?°Â¤ 2 mg/dl), SGOT / SGPT (ââ?°Â¤ 3 X ULN, Bilirubin \<2\.0 mg/dl)
  • f. First cycle of highly emetogenic chemotherapy defined as
  • 1\. Cisplatin at dose ââ?°Â¥70mg/m2 with or without other agents
  • 2\. Single agent Anthracycline (Doxorubicin ââ?°Â¥ 60mg/m2, Epirubicin ââ?°Â¥ 90mg/m2\)
  • 3\. AC (Doxorubicin ââ?°Â¥ 60mg/m2, Epirubicin ââ?°Â¥ 90mg/m2 \+ Cyclophosphamide ââ?°Â¥
  • 4\. Dacarbazine based therapy (ABVD)

Exclusion Criteria

  • a. Patient receiving concurrent quinolone, amifostine, warfarin, OCP, psychiatric drugs, Benzodiazepines, Anti\-convulsant drugs, strong or moderate CYP3A4 inhibitors (diltiazem, Ketoconazole), strong CYP3A4 inducers (rifampicin), pimozide, cisapride, terfenadine, astemizole, CYP1A2 inhibitors (ciprofloxacin, fluvoxamine)
  • b. History of chronic alcoholism
  • c. Hypersensitivity to any of the drugs used in the study {Olanzapine, NK\-1 antagonist (Fosaprepitant), 5\-HT3 antagonist ââ?¬â?? Ondansetron}
  • d. On systemic steroids, active smoker
  • e. History of any uncontrolled systemic disease including hypertension, thyroid, CNS, renal, CHF and MI in last 6 months and requiring hemodialysis, psychiatric disorder
  • f. Symptomatic Brain metastasis / Carcinomatous Meningitis
  • g. History of nausea and vomiting in 24 hours prior to first dose of chemotherapy
  • i. Use of anti\-emetic drugs (5\-HT3 Antagonist) in last 48 hours
  • j. Started on opioids in last 48 hours
  • l. Female who are pregnant, lactating

Outcomes

Primary Outcomes

Not specified

Similar Trials